Ison v. EI DuPont De Nemours and Co.

729 A.2d 832, 1999 Del. LEXIS 180, 1999 WL 360269
CourtSupreme Court of Delaware
DecidedMay 25, 1999
Docket416, 1998
StatusPublished
Cited by58 cases

This text of 729 A.2d 832 (Ison v. EI DuPont De Nemours and Co.) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ison v. EI DuPont De Nemours and Co., 729 A.2d 832, 1999 Del. LEXIS 180, 1999 WL 360269 (Del. 1999).

Opinion

VEASEY, Chief Justice:

In this forum non conveniens case, we reverse the trial court’s dismissal of a tort action against the defendant. The plaintiffs are foreign families whose claims arise out of alleged birth defects, including blindness, caused by a chemical manufactured by defendant. The injuries allegedly occurred in England, Wales, Scotland and New Zealand by reason of the mothers’ *835 exposure to the chemical when used agriculturally.

In dismissing this action, the trial court listed the convenience factors traditionally used by Delaware courts in analyzing whether to dismiss an action on grounds of forum non conveniens, and concluded that, on balance, they favored the defendant. But the trial court did not mention, analyze or apply the central criterion of Delaware Supreme Court jurisprudence: that the defendant must show “overwhelming hardship” if the case is to be dismissed. Rather, the trial court concluded in a brief letter opinion merely that “there is a better forum to prosecute these matters,” meaning the various foreign fora.

We hold that a trial court, in applying the doctrine of forum non conveniens, may not rest its analysis on the conclusion that “there is a better forum.” The court must require the defendant to show that this is one of those rare cases where the drastic relief of dismissal is warranted based on a strong showing that the burden of litigating in this forum is so severe as to result in manifest hardship to the defendant.

The fact that the plaintiffs are foreign nationals does not deprive them of the presumption that their choice of forum should be respected. Although that presumption is not as strong in the case of a foreign national plaintiff as in the case of a plaintiff who resides in the forum, we need not rest our decision on that issue because of the defendant’s weak showing of hardship. Here the defendant had its principal place of business in Delaware. There were significant contacts between the defendant’s activities in Delaware and the product alleged to have caused the harm. These facts, in the context of the analysis of the traditional convenience factors, effectively negate any claim of hardship presented by the defendant sufficient to deprive these plaintiffs of their choice of forum.

Facts

This is a consolidated case, combining product liability claims filed against E.I. duPont de Nemours and Company, Inc. (“DuPont”) in the Superior Court. Prior to consolidation, the plaintiffs sued DuPont in three separate groups, each alleging that the mothers’ exposure to Benlate, a DuPont product, caused specific birth defects in their children. 1 DuPont is a Delaware corporation and has its principal place of business in Delaware.

All of the alleged exposures to Benlate occurred outside of the United States, specifically in New Zealand, England, Wales and Scotland. The Ison plaintiffs are from New Zealand and claim that the mothers’ exposure to Benlate while employed by the Christchurch City Council in city nurseries and botanic gardens caused specific birth defects in their children. 2 They filed a complaint in the Superior Court, New Castle County, alleging that job-related exposure to Benlate caused the birth defects. 3 They allege that exposure occurred over several years through ingestion, absorption, dust inhalation, resulting from planting Benlate-soaked seedlings, and planting flower bulbs dusted with Benlate. The evidence related to the Ison plaintiffs’ exposure to Benlate and their subsequent medical care is located in New Zealand.

The Bowen plaintiffs are two families, one from England and one from Wales, that allege the mothers’ use of a retail version of Benlate caused their children’s *836 birth defects. 4 The Brown plaintiffs, four families from Scotland, also claim that the mothers’ exposure to the home version of Benlate caused their children’s birth defects. 5 The Bowen and Brown plaintiffs also filed suit in Superior Court, New Castle County. All of the Bowen and Brown plaintiffs allege specific exposures to the home-use version of Benlate that occurred in residential (as distinct from job-related) settings during the mothers’ pregnancies. The evidence related to the Bowen and Brown plaintiffs’ exposures to Benlate, and subsequent medical treatment, is located in Great Britain.

Benlate is a DuPont trademark for a fungicide developed by DuPont primarily for commercial agricultural use. The only active ingredient in Benlate is benomyl, a fungicide used primarily on field crops, fruits, nuts, ornamentals, mushrooms and turfgrass. DuPont first developed beno-myl in the late 1960s and registered it in 1972. All of the initial research, development and testing of benomyl was conducted by DuPont in its facilities in and around Wilmington, Delaware. DuPont admits that most of the persons familiar with this development process are either current or former DuPont employees in the United States.

Although Benlate is a DuPont product, DuPont permits other companies to sell it pursuant to contractual arrangements. During the period of exposure alleged by the Bowen and Brown plaintiffs, DuPont’s United Kingdom subsidiary (“DuPont (U.K.)”) had entered into such a contractual arrangement with Imperial Chemical Industries pic (“I.C.I.”), an English agrochemical company, that allowed I.C.I. to market and sell Benlate for home use in the United Kingdom. This arrangement began in 1983 and involved Benlate formulated in France using benomyl manufactured at the DuPont facility in Belle, West Virginia. 6 According to the terms of its contract with DuPont (U.K.), I.C.I. was responsible for, and obtained, the necessary regulatory approval for its sale of Benlate for home use. All of the Bowen and Brown plaintiffs allege that the birth defects at issue resulted from Benlate sold by I.C.I.

During the period of exposure alleged by the Ison plaintiffs, DuPont sold Benlate for commercial agricultural use in New Zealand through its New Zealand subsidiary (“DuPont (N.Z.)”). DuPont (N.Z.) sold the Benlate at issue to the Ison plaintiffs employer, the Christchurch City Council. DuPont (N.Z.) was responsible for, and obtained, the necessary regulatory approval for the sale of Benlate in New Zealand.

Decision of the Superior Court

DuPont contends that the trial court’s dismissal of this action is warranted. The holding set forth in the trial court’s letter opinion of four pages is as follows:

In deciding a motion for Forum Non Conveniens the Court is bound by General Foods Corp. v. Cryo-Maid, Inc., Del.Supr., 198 A.2d 681 (1964). The Court must look at the six factors listed in that case when deciding such a motion.
The first factor is what law applies. Delaware does not. All of the alleged activities took place in the home land of the plaintiffs.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gavin C. Newsom v. Fox News Network, LLC
Superior Court of Delaware, 2026
Armenta v. G/O Media, Inc. d/b/a Deadspin
Superior Court of Delaware, 2024
Maric Healthcare, LLC v. Jacob Guerrero
Court of Chancery of Delaware, 2024
Soares v. Continental Motors, Inc.
Superior Court of Delaware, 2023
Timothy J. Harris v. Mary Ellen Harris
Court of Chancery of Delaware, 2023
Sperling & Slater v. SilkRoad, Inc.
Superior Court of Delaware, 2022
Qlarant, Inc. v. IP Commercialization Labs, LLC
Superior Court of Delaware, 2022
In re Coinmint, LLC
Court of Chancery of Delaware, 2021
GXP Capital v. Argonaut Manufacturing Services
Supreme Court of Delaware, 2021
Camejo v. Angelini Pharma Inc.
Superior Court of Delaware, 2021
Focus Financial Financial Partners, LLC v. Holsopple
Court of Chancery of Delaware, 2020
AlixPartners, LLP v. Giacomo Mori
Court of Chancery of Delaware, 2019

Cite This Page — Counsel Stack

Bluebook (online)
729 A.2d 832, 1999 Del. LEXIS 180, 1999 WL 360269, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ison-v-ei-dupont-de-nemours-and-co-del-1999.